Gestalt and Primaa Collaborate to Revolutionize Skin Cancer Detection with AI-Powered Dermatopathology Tools

SPOKANE, Wash. and PARIS, March 19, 2025 /PRNewswire/ — Gestalt, a leader in digital pathology innovation, and Primaa, a MedTech pioneer specializing in AI-based dermatopathology solutions, are thrilled to announce a strategic partnership. This collaboration brings Primaa’s cutting-edge AI technology for skin cancer diagnosis directly into Gestalt’s acclaimed PathFlow platform. Together, they aim to create seamless workflows for pathologists while upholding the highest levels of diagnostic precision and patient safety.

Gestalt’s PathFlow is known for its versatility, supporting primary diagnoses*, education, resident training, and research workflows. By integrating Primaa’s advanced AI algorithms, the platform now empowers pathologists with enhanced tools for detecting and quantifying tumor biomarkers in skin tissues.

This integration allows pathologists to utilize AI-driven algorithms that detect critical biomarkers in skin lesions. Through the combined offering can automatically identify lesion types—including melanoma, squamous cell carcinoma, and basal cell carcinoma—and provides detailed measurements of lesion dimensions and margins. The solution also detects automatically all perineural invasions and all mitosis objects in the melanoma. Additionally, the system prioritizes high-risk cases for immediate review, ensuring timely and accurate diagnosis.

“Partnering with Primaa to integrate their skin AI technology into PathFlow underscores our dedication to providing pathologists with state-of-the-art tools,” said Lisa-Jean Clifford, COO & Chief Strategy Officer of Gestalt. “This partnership represents a pivotal advancement in enhancing workflow efficiency and delivering superior patient care related to skin cancer.”

Fanny Sockeel, CEO at Primaa, added, “Our collaboration with Gestalt, a leader in digital pathology, marks a significant step toward integrating AI seamlessly into pathologists’ workflows. Together, we aim to empower pathologists with cutting-edge technology that supports faster, more precise diagnoses – ultimately improving patient outcomes.”

For more information about this partnership and the respective solutions, please visit Gestalt at booth #934 and Primaa at booth #820 during USCAP March 23-26, 2025.

*Following the LDT process in the US. It is under CE-IVD marking for use in Europe.

About Gestalt : Gestalt Diagnostics transforms pathology through an intelligent, configurable, vendor-neutral, and AI-driven digital workflow that provides true interoperability enabling pathologists to diagnose* diseases faster and more efficiently. Our PathFlow solution consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks, allowing them to focus on their expertise – providing invaluable experience where it matters most. To learn more, visit www.gestaltdiagnostics.com and follow @Gestalt on LinkedIn

About Primaa: Founded in 2018, Primaa is a pioneering medtech company dedicated to transforming cancer diagnostics through Artificial Intelligence. Our advanced platform leverages cutting-edge image analysis and deep learning to enhance the accuracy and efficiency of biomarkers detection for major cancers. By empowering pathologists with automated and precise insights, Primaa is helping to drive more personalized treatment strategies and ultimately improving patient outcomes. www.primaalab.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/gestalt-and-primaa-collaborate-to-revolutionize-skin-cancer-detection-with-ai-powered-dermatopathology-tools-302405250.html

SOURCE Gestalt Diagnostics